Markets
Will a federal rule preventing hospitals from charging markups on discounted Medicare drugs be officially enacted by August 15, 2026?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if the proposed federal rule to prevent hospitals from charging markups on discounted drugs for Medicare patients, as announced by the Trump administration in July 2026, is officially enacted by August 15, 2026. Official enactment refers to the formal publication of the rule in the Federal Register or confirmation by the Department of Health and Human Services.
Rules
- Market closes at 8/15/2026.
- Logic weighted resolution applies.
The current odds seem overly optimistic for this rule being enacted in just a week. Given that the administrative process has taken longer for similar regulations in the past, I’d put the chance closer to 40 percent. Hospitals will push back hard on any markup restrictions, so I’d watch for ongoing lobbying. Just feels like we need more time for consensus.
Rationale:The comment provides a reasoned analysis of the market question, referencing historical context regarding the administrative process and potential lobbying efforts. While the claim about the odds being overly optimistic is subjective, it is grounded in a logical assessment of past experiences. The weights reflect a balanced focus on relevance and logical reasoning, with some emphasis on factual accuracy due to the mention of historical processes.
The current market price reflects a high level of confidence in this being enacted, but I think it's overstated. The pushback from hospitals and potential legal challenges could delay any final rule. Historical context shows that similar reforms often take longer than expected to materialize. I'd put the base rate for enactment closer to 55% rather than the current levels.
Rationale:The comment provides a reasoned analysis of the market's confidence level, citing potential pushback and historical context, which is mostly accurate but lacks specific evidence for the claims about delays. The logical structure is sound, with no significant fallacies present, and it directly addresses the market question. The weights reflect the importance of factual accuracy and logical reasoning in this context.
The current price implies a 75% chance of this rule being enacted by the deadline. Given the pushback from hospitals and the complexities of healthcare policy, I think the actual probability is closer to 60%. There are just too many vested interests that don’t want this change. What do you all think?
Rationale:The comment provides a reasonable assessment of the probability of the rule being enacted, referencing the current market price and the complexities of healthcare policy. While the claim about the 75% chance is accurate based on market data, the assertion of a 60% probability is subjective but logically sound. The weights reflect a balance between factual accuracy and logical reasoning, with a slight emphasis on relevance due to the direct connection to the market question.
I think there's a good chance this rule gets enacted by the deadline; the pressure from both public opinion and healthcare advocates has been building. However, the healthcare industry definitely has a way of pushing back, so I'm not fully convinced it's a done deal yet.
Rationale:The comment presents a balanced view on the likelihood of the rule being enacted, acknowledging both public support and potential pushback from the healthcare industry. The claims are mostly accurate, but the lack of specific data or evidence slightly lowers the Fact Check score. The comment is relevant to the market question and free from logical fallacies, leading to a higher score in those areas. The weights reflect the importance of factual accuracy and logical reasoning in this context.
This seems unlikely to pass by mid-August. Historical trends show regulatory changes often take longer. The current spread suggests a low probability, but I wouldn't be surprised if it shifts closer to the deadline.
Rationale:The comment provides a reasonable assessment of the likelihood of the rule passing based on historical trends and current market indicators, which supports a solid fact check score. It avoids logical fallacies and remains relevant to the market question, though it could benefit from more specific data to strengthen its claims. The weights reflect a balanced focus on factual accuracy and logical reasoning, given the comment's analytical nature.
i'm thinking there's a good chance this rule won’t get enacted by the deadline. the hospital lobby has been really strong in pushing back against similar rules before, and they've got a lot of influence. plus, with the current political climate agreeing on anything can be tough. looks like there's some uncertainty in the market, but i'm thinking the price is a bit too optimistic right now.
Rationale:The comment presents a reasonable perspective on the potential challenges to the enactment of the rule, citing the influence of the hospital lobby and the current political climate. While the claims about the hospital lobby's influence are generally accurate, they lack specific evidence, leading to a score of 70 for Fact Check. The comment is logically sound and relevant to the market question, hence the higher scores in No Fallacies and Relevance. The weights reflect the importance of logical reasoning and relevance in this context, given the speculative nature of the comment.
i doubt this one goes through by the deadline, there's been too much pushback from hospitals and lobbying groups. could be a tough sell for the feds.
Rationale:The comment expresses skepticism about the enactment of the rule due to pushback from hospitals and lobbying groups, which is a relevant concern. However, it lacks specific evidence to support the claim of significant pushback, leading to a slightly lower fact-check score. The comment is logically sound with no major fallacies, but it does rely somewhat on emotional appeal regarding the challenges faced by the federal government. Weights reflect the importance of relevance and fact-checking in this context, given the comment's focus on the market question.
this market seems low, there's a strong push for drug pricing reforms and the deadline's pretty close.
Rationale:The comment accurately reflects the ongoing discussions around drug pricing reforms, which supports its relevance. However, it lacks specific evidence or data to substantiate the claim about the market being low, leading to a slightly lower fact check score. The comment is logically sound with no fallacies detected, and it balances reasoning with some emotional appeal regarding urgency.
this seems way too optimistic. the lobbying from pharma and hospitals is gonna be intense, and they’ve got lots of cash to throw around. i wouldn’t be surprised if this gets pushed back or watered down. betting against this one.
Rationale:The comment presents a reasonable perspective on the potential influence of lobbying from pharmaceutical companies and hospitals, which is a relevant concern regarding the enactment of the federal rule. However, it lacks specific evidence to support the claims about lobbying intensity and financial influence, leading to a slightly lower score for factual accuracy. The comment is mostly logical, with some emotional appeal, hence the balanced weights reflecting the importance of relevance and logical reasoning.
This feels like a classic case of government overreach. I doubt there’s enough support to actually get this rule passed by mid-August; too many stakeholders with opposing interests. The risk here seems high for those betting on a yes.
Rationale:The comment presents a subjective opinion on government overreach and expresses doubt about the rule's passage, which is a reasonable perspective but lacks specific factual evidence to support the claim of insufficient support. The comment is relevant to the market question, discussing the potential challenges and risks involved, but it leans slightly on emotional appeal. The weights reflect the need for a balance between factual accuracy and logical reasoning given the speculative nature of the comment.